Déjà Vu: GlaxoSmithKline(GSK) Recycles Its Problematic Adjuvant into Covid-19 Vaccines

Among the 100 or so global players now working on experimental Covid-19 vaccines, most of the entities touted as frontrunners are obscure biotechnology and nanotechnology firms. Despite their focus on razzle-dazzle “next-generation” Continue ReadingDéjà Vu: GlaxoSmithKline(GSK) Recycles Its Problematic Adjuvant into Covid-19 Vaccines